1,500 Milligrams a Day, a Quarter-Millimeter of Cartilage: the Split Verdict on Glucosamine

Consider what a decision about glucosamine actually involves. One and a half grams per day — 1,500 mg, the typical American over-the-counter dose. A molecule the body already makes from glucose, an amino sugar used to build the glycosaminoglycans and proteoglycans that form joint cartilage. In some countries, prescription crystalline glucosamine sulfate, regulated as a drug and classified as a symptomatic slow-acting drug for osteoarthritis; in the United States, a bottle on the supplement shelf. It is among the most widely sold dietary supplements on earth.

The inventory of evidence is stranger. Three years of daily pills in a landmark randomized trial of 212 people, with knee X-rays read in hundredths of a millimeter. A large NIH trial called GAIT. A hazard ratio of 0.85 computed from UK Biobank questionnaires. One professional society offering conditional support, two others recommending against. And in the fine print: a warfarin interaction, a shellfish-allergy caution, a question mark over blood glucose.

The question underneath all of it is simple — does swallowing this amino sugar preserve aging knees, and does the mortality signal mean anything? The honest answer: the trial record is genuinely split, and the lifespan association is observational inference of the most confounded kind.

The best case: joint space, in fractions of a millimeter

The strongest structural evidence comes from that three-year trial of prescription crystalline glucosamine sulfate. Placebo patients lost significant knee joint space — minus 0.31 mm — while glucosamine patients essentially did not, at minus 0.06 mm, and symptoms improved on the supplement. For pain, a 2016 multicenter non-inferiority trial found combined chondroitin sulfate and glucosamine comparable to celecoxib in painful knee osteoarthritis, and a 2018 meta-analysis of randomized controlled trials supports effectiveness with a good safety profile. On paper, that is a real signal.

The counterweight: GAIT, JAMA, and the guideline split

But the inventory has a second column. The larger NIH GAIT trial found glucosamine alone no better than placebo overall. A 2018 JAMA meta-analysis judged long-term pain control uncertain for all agents in this class. And the professional guidelines split down the middle: ESCEO offers conditional support; the ACR and AAOS recommend against. A literature that genuinely persuaded everyone would not produce that map.

The mortality item — association, with a warning label

Then there is the finding that travels furthest online. Large prospective cohorts — UK Biobank, and a US NHANES cohort — link habitual glucosamine use to lower all-cause mortality (hazard ratio 0.85 in the Biobank analysis), and to lower cardiovascular disease and type 2 diabetes risk; the NHANES analysis found a similar pattern for combined glucosamine and chondroitin use. A 2022 Mendelian randomization study has even probed the genetic angle, asking whether the association survives a design built to resist confounding. But these are observational designs; they cannot establish causation, and published critiques point at selection and healthy-user bias — people who faithfully take a joint supplement differ from people who do not, in ways no questionnaire fully captures.

Practical meaning

For someone with knee osteoarthritis, a time-limited trial of glucosamine sulfate is a defensible conversation with a clinician — the safety record is generally good, with cautions around warfarin, shellfish allergy, and blood glucose. For someone buying it for longevity, the 0.85 hazard ratio is a correlation between a habit and a population, not a mechanism. And the evidence describes the compound across many formulations and brands — not this specific commercial product.

The strangest item on the list remains the X-ray: a quarter-millimeter of preserved joint space, three years in the earning. That is either the sound of cartilage being saved, or the sound of a very small number doing a very great deal of work. Educational, not medical advice.